

Anna Orlova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/536085/publications.pdf>

Version: 2024-02-01

219
papers

7,908
citations

44042

48
h-index

74108

75
g-index

221
all docs

221
docs citations

221
times ranked

4455
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. <i>Cancer Research</i> , 2006, 66, 4339-4348.	0.4	462
2	Molecular Imaging of <i>HER2</i> -Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹ In- or ⁶⁸ Ga-Labeled Affibody Molecules. <i>Journal of Nuclear Medicine</i> , 2010, 51, 892-897.	2.8	271
3	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸ Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016, 6, 262-271.	4.6	204
4	Radionuclide Therapy of HER2-Positive Microxenografts Using a ¹⁷⁷ Lu-Labeled HER2-Specific Affibody Molecule. <i>Cancer Research</i> , 2007, 67, 2773-2782.	0.4	203
5	Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors. <i>Cancer Research</i> , 2007, 67, 2178-2186.	0.4	176
6	Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule. <i>Journal of Molecular Biology</i> , 2008, 376, 1388-1402.	2.0	138
7	On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a ¹²⁴ I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model. <i>Journal of Nuclear Medicine</i> , 2009, 50, 417-425.	2.8	131
8	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 555-568.	1.4	117
9	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1135-1146.	3.3	112
10	Slow Internalization of Anti-HER2 Synthetic Affibody Monomer ¹¹¹ In-DOTA-Z _{HER2:342-pep2} : Implications for Development of Labeled Tracers. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 435-442.	0.7	108
11	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR ¹¹¹ In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 613-622.	3.3	103
12	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , 2018, 59, 885-891.	2.8	101
13	^{99m} Tc-maEEE-Z _{HER2:342} , an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors. <i>Bioconjugate Chemistry</i> , 2007, 18, 1956-1964.	1.8	98
14	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry. <i>Journal of Nuclear Medicine</i> , 2009, 50, 274-283.	2.8	98
15	Targeting of HER2-Expressing Tumors with a Site-Specifically ^{99m} Tc-Labeled Recombinant Affibody Molecule, Z _{HER2:2395} , with C-Terminally Engineered Cysteine. <i>Journal of Nuclear Medicine</i> , 2009, 50, 781-789.	2.8	97
16	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. <i>Lancet Oncology</i> , The, 2010, 11, 992-1000.	5.1	91
17	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸ Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.	2.8	88
18	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the ^{99m} Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 722-733.	3.3	84

#	ARTICLE	IF	CITATIONS
19	Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2008, 19, 235-243.	1.8	83
20	Targeting of HER2-Expressing Tumors Using ¹¹¹ In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1131-1138.	2.8	81
21	Molecular Design and Optimization of ^{99m} Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties. <i>Journal of Nuclear Medicine</i> , 2011, 52, 461-469.	2.8	80
22	^{99m} Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1843-1853.	3.3	79
23	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 80-90.	1.6	78
24	A HER2-binding Affibody molecule labelled with ⁶⁸ Ga for PET imaging: direct in vivo comparison with the ¹¹¹ In-labelled analogue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1356-1367.	3.3	75
25	Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein. <i>Journal of Nuclear Medicine</i> , 2013, 54, 961-968.	2.8	75
26	HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [^{99m} Tc(CO) ₃] ⁺ , and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation. <i>Bioconjugate Chemistry</i> , 2010, 21, 2013-2022.	1.8	72
27	Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition. <i>Journal of Nuclear Medicine</i> , 2012, 53, 953-960.	2.8	72
28	¹¹¹ In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , 2006, 47, 846-53.	2.8	72
29	Development and preclinical characterisation of ^{99m} Tc-labelled Affibody molecules with reduced renal uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2245-2255.	3.3	69
30	Direct Targeting Options for STAT3 and STAT5 in Cancer. <i>Cancers</i> , 2019, 11, 1930.	1.7	65
31	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. <i>Journal of Nuclear Medicine</i> , 2006, 47, 512-9.	2.8	65
32	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 631-638.	3.3	64
33	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. <i>Drug Discovery Today</i> , 2012, 17, 1224-1232.	3.2	64
34	Influence of Labelling Methods on Biodistribution and Imaging Properties of Radiolabelled Peptides for Visualisation of Molecular Therapeutic Targets. <i>Current Medicinal Chemistry</i> , 2010, 17, 2636-2655.	1.2	63
35	Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging. <i>Bioconjugate Chemistry</i> , 2013, 24, 1144-1153.	1.8	62
36	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. <i>PLoS ONE</i> , 2013, 8, e62791.	1.1	61

#	ARTICLE	IF	CITATIONS
37	<i>Update:</i> Affibody Molecules for Molecular Imaging and Therapy for Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 573-584.	0.7	58
38	Affibody-mediated PET imaging of HER3 expression in malignant tumours. <i>Scientific Reports</i> , 2015, 5, 15226.	1.6	56
39	Affibody Molecules as Targeting Vectors for PET Imaging. <i>Cancers</i> , 2020, 12, 651.	1.7	56
40	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a ⁶⁸ Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. <i>Molecules</i> , 2014, 19, 10455-10472.	1.7	55
41	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , 2015, 75, 4364-4371.	0.4	55
42	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 692-701.	3.3	54
43	HAHAHA, HEHEHE, HIIHII, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [^{99m} Tc(CO) ₃] ⁺ -Labeled Affibody Molecules. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4966-4974.	2.9	54
44	In Vivo Evaluation of Cysteine-Based Chelators for Attachment of ^{99m} Tc to Tumor-Targeting Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2007, 18, 549-558.	1.8	53
45	Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with ^{99m} Tc, ¹¹¹ In, and ¹²⁵ I. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3817-3826.	2.9	53
46	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. <i>Theranostics</i> , 2016, 6, 93-103.	4.6	53
47	Influence of Macrocyclic Chelators on the Targeting Properties of ⁶⁸ Ga-Labeled Synthetic Affibody Molecules: Comparison with ¹¹¹ In-Labeled Counterparts. <i>PLoS ONE</i> , 2013, 8, e70028.	1.1	50
48	Imaging of Platelet-Derived Growth Factor Receptor $\alpha 2$ Expression in Glioblastoma Xenografts Using Affibody Molecule ¹¹¹ In-DOTA-Z09591. <i>Journal of Nuclear Medicine</i> , 2014, 55, 294-300.	2.8	50
49	PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹ Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016, 48, 1325-1332.	1.4	50
50	Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti-HER2 Affibody. <i>Bioconjugate Chemistry</i> , 2005, 16, 1547-1555.	1.8	49
51	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. <i>International Journal of Oncology</i> , 2010, 36, 757-63.	1.4	49
52	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1092-1098.	2.8	48
53	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 531-539.	3.3	46
54	The effect of macrocyclic chelators on the targeting properties of the ⁶⁸ Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. <i>Nuclear Medicine and Biology</i> , 2015, 42, 446-454.	0.3	46

#	ARTICLE	IF	CITATIONS
55	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. <i>Journal of Nuclear Medicine</i> , 2016, 57, 431-436.	2.8	46
56	Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFR ^β Expression in Vivo. <i>Molecular Pharmaceutics</i> , 2014, 11, 3957-3964.	2.3	45
57	Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of ^{99m} Tc-Labeled Anti-HER2 Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2008, 19, 2568-2576.	1.8	44
58	Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹ In-DOTA-Z _{IGF1R:4551} . <i>Journal of Nuclear Medicine</i> , 2012, 53, 90-97.	2.8	44
59	In Vitro and In Vivo Evaluation of a ¹⁸ F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging. <i>PLoS ONE</i> , 2013, 8, e81932.	1.1	44
60	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1864-1873.	3.3	43
61	Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with ⁶⁸ Ga and ¹¹¹ In via Maleimido Derivatives of DOTA and NODAGA. <i>Bioconjugate Chemistry</i> , 2013, 24, 1102-1109.	1.8	43
62	¹⁸⁶ Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 260-269.	3.3	41
63	Phase I Study of ^{99m} Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 493-499.	2.8	41
64	Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides. <i>Current Medicinal Chemistry</i> , 2003, 10, 2447-2460.	1.2	40
65	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with ¹¹¹ In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 481-492.	3.3	40
66	Methods for Radiolabelling of Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2014, 1060, 309-330.	0.4	40
67	Imaging of HER3-expressing xenografts in mice using a ^{99m} Tc(CO) ₃ -HEHEHE-ZHER3:08699 affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1450-1459.	3.3	40
68	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. <i>Journal of Controlled Release</i> , 2018, 288, 84-95.	4.8	40
69	[^{99m} Tc(CO) ₃] ⁺ -(HE) ₃ -ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 439-449.	3.3	38
70	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. <i>Bioconjugate Chemistry</i> , 2016, 27, 716-726.	1.8	38
71	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 16.	1.8	38
72	Cellular processing of ¹²⁵ I- and ¹¹¹ In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. <i>Nuclear Medicine and Biology</i> , 2000, 27, 827-835.	0.3	36

#	ARTICLE	IF	CITATIONS
73	Evaluation of a Maleimido Derivative of CHX-A ϵ^2 DTPA for Site-Specific Labeling of Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2008, 19, 1579-1587.	1.8	35
74	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. <i>Molecular Pharmaceutics</i> , 2019, 16, 995-1008.	2.3	35
75	Closo-Dodecaborate(2-) as a Linker for Iodination of Macromolecules. Aspects on Conjugation Chemistry and Biodistribution. <i>Bioconjugate Chemistry</i> , 1999, 10, 338-345.	1.8	34
76	Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of ¹¹¹ In-Labeled Synthetic Anti-HER2 Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2012, 23, 1661-1670.	1.8	34
77	Optimal composition and position of histidine-containing tags improves biodistribution of ^{99m} Tc-labeled DARPin G3. <i>Scientific Reports</i> , 2019, 9, 9405.	1.6	34
78	Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors. <i>Molecular Imaging and Biology</i> , 2010, 12, 54-62.	1.3	33
79	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. <i>Molecular Pharmaceutics</i> , 2016, 13, 1668-1678.	2.3	33
80	Cyclic versus Noncyclic Chelating Scaffold for ⁸⁹ Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. <i>Molecular Pharmaceutics</i> , 2018, 15, 175-185.	2.3	31
81	<i>In Vivo</i> and <i>In Vitro</i> Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2013, 28, 187-195.	0.7	30
82	Comparative evaluation of ¹¹¹ In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. <i>Oncology Reports</i> , 2015, 34, 1042-1048.	1.2	30
83	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of <i>In Vivo</i> Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , 2016, 13, 3676-3687.	2.3	30
84	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.4	30
85	Trastuzumab cotreatment improves survival of mice with PC ϵ prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷ Lu ϵ DOTAGA ϵ PEG ₂ ϵ RM26. <i>International Journal of Cancer</i> , 2019, 145, 3347-3358.	2.3	30
86	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. <i>International Journal of Oncology</i> , 2016, 48, 2124-2134.	1.4	29
87	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. <i>Scientific Reports</i> , 2017, 7, 5961.	1.6	29
88	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. <i>Journal of Nuclear Medicine</i> , 2018, 59, 93-99.	2.8	29
89	Phase I Trial of ^{99m} Tc-(HE) ₃ -G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 528-535.	2.8	29
90	Comparative biodistribution of imaging agents for <i>in vivo</i> molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on ¹¹¹ In- and ¹²⁵ I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1093-1102.	0.3	28

#	ARTICLE	IF	CITATIONS
91	The influence of Bz-DOTA and CHX-Aâ€³-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1460-1468.	3.3	27
92	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016, 49, 2285-2293.	1.4	27
93	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-10.	0.4	27
94	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. <i>Seminars in Cancer Biology</i> , 2021, 72, 185-197.	4.3	27
95	Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1348-1356.	3.3	26
96	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. <i>Cancers</i> , 2019, 11, 1371.	1.7	26
97	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , 2007, 19, 285-91.	1.8	26
98	Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules. <i>Bioconjugate Chemistry</i> , 2011, 22, 894-902.	1.8	25
99	Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with ¹⁸ F-4-Fluorobenzaldehyde. <i>Bioconjugate Chemistry</i> , 2014, 25, 82-92.	1.8	25
100	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , 2018, 8, 4462-4476.	4.6	25
101	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. <i>Nuclear Medicine and Biology</i> , 2005, 32, 613-622.	0.3	24
102	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. <i>International Journal of Oncology</i> , 2016, 49, 1185-1194.	1.4	24
103	¹⁸⁸ Re-Z _{HER2:V2} , a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1842-1848.	2.8	23
104	Optimized indirect 76br-bromination of antibodies using n-succinimidyl para-[76br]bromobenzoate for radioimmuno PET. <i>Nuclear Medicine and Biology</i> , 2000, 27, 837-843.	0.3	22
105	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-Aâ€³DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 523-528.	0.8	22
106	Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. <i>Amino Acids</i> , 2015, 47, 303-315.	1.2	22
107	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. <i>Scientific Reports</i> , 2018, 8, 2998.	1.6	22
108	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. <i>Tumor Biology</i> , 2012, 33, 641-651.	0.8	21

#	ARTICLE	IF	CITATIONS
109	Preclinical Evaluation of [⁶⁸ Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. <i>Cells</i> , 2018, 7, 141.	1.8	21
110	Selection of the optimal macrocyclic chelators for labeling with ¹¹¹ In and ⁶⁸ Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 140, 109-120.	2.0	21
111	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of ⁶⁸ Ga-Labeled Tracers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1080.	1.8	21
112	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 134, 37-48.	2.0	21
113	Pre-clinical evaluation of [¹¹¹ In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. <i>International Journal of Molecular Medicine</i> , 2007, 20, 397-404.	1.8	21
114	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. <i>International Journal of Oncology</i> , 2011, 40, 1677-82.	1.4	20
115	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017, 7, 43118.	1.6	20
116	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPIn Ec1. <i>International Journal of Biological Macromolecules</i> , 2020, 145, 216-225.	3.6	20
117	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸ Re. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 519-528.	2.6	19
118	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. <i>Cells</i> , 2018, 7, 164.	1.8	19
119	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3394-3403.	2.3	19
120	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. <i>Biomaterials</i> , 2019, 203, 73-85.	5.7	19
121	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPIn) G3 variants for molecular imaging of HER2. <i>International Journal of Oncology</i> , 2019, 54, 1209-1220.	1.4	19
122	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. <i>Pharmaceutics</i> , 2020, 12, 614.	2.0	19
123	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. <i>Journal of Labelled Compounds and Radiopharmaceutics</i> , 2000, 43, 251-260.	0.5	18
124	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , 2019, 9, 655.	1.6	18
125	Indirect Radioiodination of DARPIn G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3047.	1.8	18
126	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3663.	1.8	18

#	ARTICLE	IF	CITATIONS
127	Positioning of ^{99m} Tc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3912-3914.	1.0	17
128	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , 2017, 7, 14780.	1.6	17
129	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. <i>Pharmaceutics</i> , 2019, 11, 358.	2.0	17
130	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPIn Ec1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3310.	1.8	17
131	Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. <i>PLoS ONE</i> , 2014, 9, e107483.	1.1	17
132	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. <i>Applied Materials Today</i> , 2021, 25, 101199.	2.3	17
133	[¹¹¹ In]Bz-DTPA-hEGF: Preparation and In Vitro Characterization of a Potential Anti-Glioblastoma Targeting Agent. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 643-654.	0.7	16
134	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of ^{99m} Tc-labeled recombinant Affibody molecules. <i>Amino Acids</i> , 2012, 42, 1975-1985.	1.2	16
135	Synthesis of ¹¹ C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [¹¹ C]CO. <i>ChemistryOpen</i> , 2016, 5, 566-573.	0.9	16
136	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of ^{99m} Tc-labeled anti-EGFR affibody molecules. <i>Amino Acids</i> , 2018, 50, 981-994.	1.2	16
137	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. <i>Cancers</i> , 2021, 13, 85.	1.7	16
138	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹ In using a maleimido derivative of NODAGA. <i>Nuclear Medicine and Biology</i> , 2012, 39, 518-529.	0.3	15
139	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 378-386.	0.3	15
140	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹ In and ⁶⁸ Ga. <i>Molecular Pharmaceutics</i> , 2018, 15, 2674-2683.	2.3	15
141	Comparative Biodistribution of the Radiohalogenated (Br, I and At) Antibody A33. Implications for In Vivo Dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 385-396.	0.7	14
142	Labelling chemistry and characterization of [^{90Y/177Lu}]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , 2007, 19, 285.	1.8	14
143	Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. <i>Biopolymers</i> , 2009, 92, 116-123.	1.2	14
144	Development of a ¹²⁴ I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. <i>International Journal of Oncology</i> , 2014, 44, 1998-2008.	1.4	14

#	ARTICLE	IF	CITATIONS
145	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with ⁶⁴ Cu Using NOTA and NODAGA. Contrast Media and Molecular Imaging, 2017, 2017, 1-12.	0.4	14
146	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Scientific Reports, 2019, 9, 17086.	1.6	14
147	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Scientific Reports, 2019, 9, 14907.	1.6	14
148	Increase in negative charge of ⁶⁸ Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports, 2019, 9, 17710.	1.6	14
149	Preclinical Evaluation of ^{99m} Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. International Journal of Molecular Sciences, 2021, 22, 2770.	1.8	14
150	Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2275-2292.	0.9	14
151	Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer: Comparison of cellular processing of [¹¹¹ In]-labeled affibody molecule ZEGFR:2377 and cetuximab. International Journal of Oncology, 2011, 38, 1137-43.	1.4	13
152	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. Bioconjugate Chemistry, 2016, 27, 2678-2688.	1.8	13
153	Molecular design of radiocopper-labelled Affibody molecules. Scientific Reports, 2018, 8, 6542.	1.6	13
154	The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. Haematologica, 2019, 104, 1907-1909.	1.7	13
155	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [¹¹¹ In]DTPA-hEGF and [¹¹¹ In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-501.	0.7	13
156	[¹⁷⁷ Lu]Bz-DTPA-EGF: Preclinical Characterization of a Potential Radionuclide Targeting Agent Against Glioma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 195-204.	0.7	12
157	Comparative Biodistribution of Potential Anti- Glioblastoma Conjugates [¹¹¹ In]DTPA-hEGF and [¹¹¹ In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-502.	0.7	12
158	Position for Site-Specific Attachment of a DOTA Chelator to Synthetic Affibody Molecules Has a Different Influence on the Targeting Properties of ⁶⁸ Ga-Compared to ¹¹¹ In-Labeled Conjugates. Molecular Imaging, 2014, 13, 7290.2014.00034.	0.7	12
159	Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. ChemistryOpen, 2015, 4, 174-182.	0.9	12
160	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. Cancers, 2019, 11, 1168.	1.7	12
161	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. Scientific Reports, 2020, 10, 20777.	1.6	12
162	Comparative Evaluation of Novel ¹⁷⁷ Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. Cancers, 2021, 13, 500.	1.7	12

#	ARTICLE	IF	CITATIONS
163	In Vitro Characterization of ²¹¹ At-Labeled Antibody A33 as a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 514-523.	0.7	11
164	Direct comparison of ¹¹¹ In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 693-702.	3.3	11
165	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 820-824.	1.0	11
166	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. <i>Scientific Reports</i> , 2018, 8, 9643.	1.6	11
167	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPIn Ec1. <i>Molecules</i> , 2020, 25, 4719.	1.7	11
168	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. <i>Biomaterials</i> , 2021, 266, 120381.	5.7	11
169	Preparation and in vitro evaluation of ¹¹¹ In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. <i>Human Antibodies</i> , 2010, 19, 107-111.	0.6	10
170	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , 2017, 51, 1765-1774.	1.4	10
171	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of <i>Pseudomonas</i> exotoxin A. <i>International Journal of Oncology</i> , 2019, 55, 309-319.	1.4	10
172	⁶⁶ Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [⁶⁶ Ga]Ga-NOTA-PEG2-RM26. <i>Scientific Reports</i> , 2021, 11, 3631.	1.6	10
173	The Use of a Non-Conventional Long-Lived Gallium Radioisotope ⁶⁶ Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. <i>Pharmaceutics</i> , 2021, 13, 292.	2.0	10
174	[^{99m} Tc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. <i>Oncology Reports</i> , 2005, 13, 1169-75.	1.2	10
175	Radio-iodination of monoclonal antibody using potassium [¹²⁵ I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). <i>Anticancer Research</i> , 2006, 26, 1217-23.	0.5	10
176	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , 2020, 12, 551.	2.0	9
177	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1972.	1.8	9
178	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. <i>Current Medicinal Chemistry</i> , 2020, 27, 7090-7111.	1.2	9
179	Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1046-1051.	2.8	9
180	Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the ¹¹¹ In-labeled conjugate. <i>Nuclear Medicine and Biology</i> , 2011, 38, 697-706.	0.3	8

#	ARTICLE	IF	CITATIONS
181	In vitro modeling of HER2-targeting therapy in disseminated prostate cancer. <i>International Journal of Oncology</i> , 2014, 45, 2153-2158.	1.4	8
182	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019, 9, 6779.	1.6	8
183	Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. <i>Pharmaceutics</i> , 2020, 12, 977.	2.0	8
184	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. <i>Pharmaceutics</i> , 2021, 13, 430.	2.0	8
185	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. <i>Cancers</i> , 2021, 13, 3939.	1.7	8
186	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. <i>Anticancer Research</i> , 2004, 24, 4035-41.	0.5	8
187	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. <i>International Journal of Molecular Medicine</i> , 2007, 19, 485-93.	1.8	8
188	Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. <i>Pharmaceutics</i> , 2022, 14, 1098.	2.0	8
189	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1312.	1.8	7
190	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , 2020, 12, 391.	2.0	7
191	Preclinical Evaluation of ^{99m} Tc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. <i>Pharmaceutics</i> , 2021, 13, 182.	2.0	7
192	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPIn Ec1. <i>Cancers</i> , 2021, 13, 3589.	1.7	7
193	Targeting of a Head and Neck Squamous Cell Carcinoma Xenograft Model Using the Chimeric Monoclonal Antibody U36 Radioiodinated with a closo-Dodecaborate-containing Linker. <i>Acta Oto-Laryngologica</i> , 2004, 124, 1078-1085.	0.3	6
194	Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients. <i>Oncology Letters</i> , 2015, 9, 950-954.	0.8	6
195	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. <i>Pharmaceutics</i> , 2019, 11, 380.	2.0	6
196	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. <i>Molecules</i> , 2020, 25, 5993.	1.7	6
197	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. <i>Bulletin of Siberian Medicine</i> , 2021, 20, 23-30.	0.1	6
198	HER3 PET Imaging: ⁶⁸ Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to ⁸⁹ Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , 2021, 13, 4791.	1.7	6

#	ARTICLE	IF	CITATIONS
199	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. <i>International Journal of Molecular Medicine</i> , 0, , .	1.8	6
200	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. <i>Pharmaceutics</i> , 2021, 13, 1974.	2.0	6
201	Title is missing!. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2000, 246, 207-213.	0.7	5
202	Title is missing!. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2003, 256, 67-71.	0.7	5
203	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2004, 260, 295-299.	0.7	5
204	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. <i>European Journal of Organic Chemistry</i> , 2004, 2004, 3719-3725.	1.2	5
205	Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. <i>Scientific Reports</i> , 2020, 10, 18148.	1.6	5
206	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody [®] Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. <i>Pharmaceutics</i> , 2021, 13, 839.	2.0	5
207	Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. <i>Pharmaceutics</i> , 2022, 14, 1092.	2.0	5
208	Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer [®] devices. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2015, 304, 823-828.	0.7	4
209	Affibody [®] -mediated imaging of EGFR expression in prostate cancer using radiocobalt ⁶⁰ -labeled DOTA [®] -ZEGFR:2377. <i>Oncology Reports</i> , 2018, 41, 534-542.	1.2	4
210	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. <i>Pharmaceutics</i> , 2021, 13, 1847.	2.0	4
211	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. <i>Pharmaceutics</i> , 2022, 14, 1475.	2.0	4
212	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2002, 251, 409-412.	0.7	2
213	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. <i>Radiochimica Acta</i> , 2004, 92, 311-315.	0.5	2
214	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation. <i>Oncology Reports</i> , 0, , .	1.2	2
215	Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated. <i>Oncology Reports</i> , 0, , .	1.2	2
216	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. <i>Pharmaceutics</i> , 2022, 14, 522.	2.0	2

#	ARTICLE	IF	CITATIONS
217	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022, 10, 1293.	1.4	2
218	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6181.	1.7	1
219	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay. <i>International Journal of Oncology</i> , 2005, 27, 1355.	1.4	0